AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
BioXcel's BXCL501 shows positive results in treating agitation episodes in bipolar and schizophrenia patients.
ByAinvest
Wednesday, Aug 27, 2025 8:04 am ET1min read
BioXcel Therapeutics has announced positive results from its SERENITY At-Home trial for BXCL501, a treatment for agitation episodes in patients with bipolar disorders or schizophrenia. The trial achieved its primary endpoint of tolerability and showed continued effects with repeat dosing. BioXcel plans to submit a supplemental new drug application (sNDA) to the FDA in Q1 2026 for expanded usage of BXCL501 in the outpatient setting without healthcare supervision. The trial treated over 2400 episodes of agitation, suggesting a significant market opportunity.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet